Ibio Inc (IBIO)

Currency in USD
0.7913
-0.0627(-7.34%)
Closed·
0.7718-0.0195(-2.46%)
·
IBIO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.78110.8539
52 wk Range
0.55626.8908
Key Statistics
Prev. Close
0.854
Open
0.85
Day's Range
0.7811-0.8539
52 wk Range
0.5562-6.8908
Volume
451.24K
Average Volume (3m)
955.04K
1-Year Change
-69.91%
Book Value / Share
0.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.2000
Upside
+430.77%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Ibio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Ibio Inc Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Compare IBIO to Peers and Sector

Metrics to compare
IBIO
Peers
Sector
Relationship
P/E Ratio
−0.8x−3.8x−0.7x
PEG Ratio
−0.010.120.00
Price/Book
1.0x0.9x2.6x
Price / LTM Sales
38.9x13.0x3.4x
Upside (Analyst Target)
-203.8%38.0%
Fair Value Upside
Unlock3.5%5.2%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.2000
(+430.77% Upside)

Earnings

Latest Release
Sep 05, 2025
EPS / Forecast
-0.36 / -0.24
Revenue / Forecast
200.00K / --
EPS Revisions
Last 90 days

IBIO Income Statement

People Also Watch

7.9600
NUKK
-11.16%
12.660
GLTO
-14.17%
0.25
CYCU
-13.54%
3.680
QCLS
-7.30%

FAQ

What Stock Exchange Does Ibio Trade On?

Ibio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Ibio?

The stock symbol for Ibio is "IBIO."

What Is the Ibio Market Cap?

As of today, Ibio market cap is 15.55M.

What Is Ibio's Earnings Per Share (TTM)?

The Ibio EPS (TTM) is -1.75.

From a Technical Analysis Perspective, Is IBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Ibio Stock Split?

Ibio has split 3 times.

How Many Employees Does Ibio Have?

Ibio has 20 employees.

What is the current trading status of Ibio (IBIO)?

As of 12 Oct 2025, Ibio (IBIO) is trading at a price of 0.7913, with a previous close of 0.85. The stock has fluctuated within a day range of 0.7811 to 0.8539, while its 52-week range spans from 0.5562 to 6.8908.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.